Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences is a late-stage clinical biopharmaceutical company

The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform posses

ses the potential for the discovery and development of the next generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs, and multiple partnered PDC assets. The company is currently enrolling in a global, pivotal Phase 2 Part B (CLOVER-WaM) expansion study in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The WM study will enroll up to 50 patients to evaluate the efficacy and safety of CLR 131 for marketing approval. For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us both here and on the company’s other social media channels: Twitter, LinkedIn, and YouTube.

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 https://bit.ly...
11/14/2024

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 https://bit.ly/4ftGAy4

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cance...
11/12/2024

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer https://bit.ly/3Z1hBfJ

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cance...
11/12/2024

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer https://bit.ly/3Z1hBfJ

Today, around the U.S., we pause to honor the service and sacrifice of our veterans. At Cellectar Biosciences, we are gr...
11/11/2024

Today, around the U.S., we pause to honor the service and sacrifice of our veterans. At Cellectar Biosciences, we are grateful for those who have bravely served our country and are proud to support our nation's heroes.💙❤️

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024h...
11/11/2024

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

https://bit.ly/3O42gow

We are thrilled to announce that Cellectar has been selected to present new data from the Phase 2 CLOVER WaM study in an...
11/07/2024

We are thrilled to announce that Cellectar has been selected to present new data from the Phase 2 CLOVER WaM study in an oral session at . Learn more: https://bit.ly/ASH2024CLRB

We are thrilled to announce that Cellectar has been selected to present new data from the Phase 2 CLOVER WaM study in an...
11/07/2024

We are thrilled to announce that Cellectar has been selected to present new data from the Phase 2 CLOVER WaM study in an oral session at . Learn more:

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 Download as PDF November 07, 2024 Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study Highlights Company’s Leadership and...

Do you or someone you love have ? Please consider our pediatric exploring a potential new treatment for kids 🎗 at w...
10/24/2024

Do you or someone you love have ? Please consider our pediatric exploring a potential new treatment for kids 🎗
at www.pediatrichggtrial.com. Check out Team Jack for more information about childhood brain cancer. 💪💪💪🎗️🎗️🎗️ 💛

If your child has been diagnosed with High-Grade Glioma, ask your doctor about our clinical trial for at www.pediatric...
10/23/2024

If your child has been diagnosed with High-Grade Glioma, ask your doctor about our clinical trial for at www.pediatrichggtrial.com. Thank you to Pediatric Cancer Research Foundation for this very informative infographic.

This week, we were proud to share important data at the IWWM conference in Prague! Our investigational agent, Iopofosine...
10/19/2024

This week, we were proud to share important data at the IWWM conference in Prague! Our investigational agent, Iopofosine I 131, was featured in two presentations, highlighting our commitment to advancing the science for those living with and treating WM.

Inspiring presentations and discussions happened in Prague at the International Workshop on Waldenstrom's Macroglobuline...
10/19/2024

Inspiring presentations and discussions happened in Prague at the International Workshop on Waldenstrom's Macroglobulinemia (IWWM)! 🎓

We’re focused on learning more about this rare disease and strategies for patient care in WM, a rare non-Hodgkin lymphoma with no current cure. With continued research and collaboration, the WM Community is making strides toward a better future for those affected, and Cellectar is honored to be playing a part in advancing the science.
Join us in spreading the word about this important cause!

This week we were in Prague at the International Workshop on Waldenstrom’s Macroglobulinemia (IWWM), where scientists an...
10/18/2024

This week we were in Prague at the International Workshop on Waldenstrom’s Macroglobulinemia (IWWM), where scientists and doctors from across the world gathered to share groundbreaking research on this rare blood cancer.

Waldenstrom’s Macroglobulinemia is a type of lymphoma that affects the bone marrow, leading to an overproduction of abnormal white blood cells. As a rare disease, it’s crucial to raise awareness and support ongoing research to help the WM community.

Together, as a WM community, we can make a difference! 💪

Address

Florham Park, NJ

Telephone

+16084418120

Website

Alerts

Be the first to know and let us send you an email when Cellectar Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cellectar Biosciences:

Shortcuts

Share

Our Story

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development (R&D) collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s lead PDC therapeutic, CLR 131, is currently in three clinical studies – a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.

The company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on our social media channels: Twitter, LinkedIn, and Facebook.